a year ago
ASRT
AnalystsThomas FlatenThomas Flaten's Stock Forecasts
AnalystsThomas Flaten
Analyst Ranking
Bottom 2%
#4475 out of 4554 analysts
Average Return
-20.94%
Win Rate
19%5 out of 26
Risk vs Reward
Poor
Good
Thomas Flaten's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Diamedica Therapeutics IncDMAC | +220.63% | $1.26 | $4.04 | 2022-07-06 - 2023-07-06 | Strong Buy |
Biolife Solutions IncBLFS | +152.95% | $15.77 | $39.89 | 2020-02-23 - 2021-02-24 | Strong Buy |
Castle Biosciences IncCSTL | +64.67% | $11.66 | $19.20 | 2023-06-04 - 2024-04-18 | Strong Buy |
Biolife Solutions IncBLFS | +20.98% | $13.11 | $15.86 | 2023-08-08 - 2024-04-18 | Strong Buy |
Achieve Life Sciences IncACHV | +4.10% | $4.39 | $4.57 | 2024-03-04 - 2024-04-18 | Strong Buy |
Thomas Flaten Analyst Color
Get additional color on Thomas Flaten's coverage of popular stocks
Thomas Flaten's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Optinose IncOPTN | 2 | Strong Buy | $4.00 | +331.03% | Maintains | a month ago |
Assertio Holdings IncASRT | 3 | Strong Buy | $3.00 | +297.88% | Maintains | a month ago |
Aquestive Therapeutics IncAQST | 1 | Strong Buy | $8.00 | +77.78% | Maintains | a month ago |
Achieve Life Sciences IncACHV | 3 | Strong Buy | $11.00 | +140.70% | Maintains | a month ago |
Checkpoint Therapeutics IncCKPT | 3 | Strong Buy | $14.00 | +775.00% | Maintains | 8 months ago |
Better Therapeutics IncBTTX | 2 | Strong Buy | $3.00 | +6,566.67% | Maintains | 8 months ago |
Biolife Solutions IncBLFS | 2 | Strong Buy | $25.00 | +57.63% | Maintains | 8 months ago |
Castle Biosciences IncCSTL | 4 | Strong Buy | $32.00 | +66.67% | Reiterates | 9 months ago |
Evaxion Biotech AEVAX | 1 | Strong Buy | $70.00 | N/A | Maintains | a year ago |
Oncocyte CorpOCX | 3 | Hold | $10.00 | N/A | Downgrades | a year ago |
Diamedica Therapeutics IncDMAC | 1 | Strong Buy | $8.00 | N/A | Maintains | 2 years ago |
Fresh Tracks Therapeutics IncFRTX | 2 | Hold | N/A | N/A | Downgrades | 2 years ago |
Ensysce Biosciences IncENSC | 1 | Strong Buy | $960.00 | N/A | Initiates Coverage On | 2 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.